313 related articles for article (PubMed ID: 3162402)
21. An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line.
Chaney SG; Gibbons GR; Wyrick SD; Podhasky P
Cancer Res; 1991 Feb; 51(3):969-73. PubMed ID: 1988140
[TBL] [Abstract][Full Text] [Related]
22. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
[TBL] [Abstract][Full Text] [Related]
23. Circumvention of platinum resistance: structure-activity relationship for homologous series of ammine/amine platinum(II) complexes in L1210 cell lines.
Yoshida M; Khokhar AR; Siddik ZH
Anticancer Drug Des; 1994 Oct; 9(5):425-34. PubMed ID: 7945726
[TBL] [Abstract][Full Text] [Related]
24. Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane)platinum(IV) carboxylate complexes.
Khokhar AR; al-Baker S; Shamsuddin S; Siddik ZH
J Med Chem; 1997 Jan; 40(1):112-6. PubMed ID: 9016335
[TBL] [Abstract][Full Text] [Related]
25. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
Goddard P; Valenti M; Kelland LR
Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
[TBL] [Abstract][Full Text] [Related]
26. Antileukemia (L1210) activity and toxicity of cis-dichlorodiammineplatinum(II) analogs.
Prestayko AW; Bradner WT; Huftalen JB; Rose WC; Schurig JE; Cleare MJ; Hydes PC; Crooke ST
Cancer Treat Rep; 1979; 63(9-10):1503-8. PubMed ID: 498150
[TBL] [Abstract][Full Text] [Related]
27. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV).
Yoshida M; Khokhar AR; Siddik ZH
Cancer Res; 1994 Sep; 54(17):4691-7. PubMed ID: 8062266
[TBL] [Abstract][Full Text] [Related]
28. Water-soluble N-substituted iminodiacetato(1,2-diaminocyclohexane)-platinum(II) complexes as potential antitumor agents.
Hacker MP; Khokhar AR; Krakoff IH; Brown DB; McCormack JJ
Cancer Res; 1986 Dec; 46(12 Pt 1):6250-4. PubMed ID: 3779645
[TBL] [Abstract][Full Text] [Related]
29. Effect of treatment schedule on antitumor activity of glycolate-0,0'-diammineplatinum(II), a new platinum derivative: comparison with cis-diamminedichloroplatinum(II).
Suzumura Y; Kato T; Ueda R; Ota K
Anticancer Res; 1989; 9(4):1083-8. PubMed ID: 2817790
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
31. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
33. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
34. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
[TBL] [Abstract][Full Text] [Related]
35. Comparative toxicity and renal distribution of the platinum analogs tetraplatin, CHIP, and cisplatin at equimolar doses in the Fischer 344 rat.
Smith JH; Smith MA; Litterst CL; Copley MP; Uozumi J; Boyd MR
Fundam Appl Toxicol; 1988 Jan; 10(1):45-61. PubMed ID: 3350229
[TBL] [Abstract][Full Text] [Related]
36. Transplacental passage of Pt after treatment with the new triamine complex cis-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N4]-chloride platinum (II) monohydrochloride monohydrate.
Ognio E; Chiavarina B; Caviglioli G; Lapide M; Viale M
Arch Toxicol; 2004 Oct; 78(10):584-8. PubMed ID: 15150682
[TBL] [Abstract][Full Text] [Related]
37. Clinical pharmacokinetics of oxaliplatin: a critical review.
Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
[TBL] [Abstract][Full Text] [Related]
38. Comparative nephrotoxicity of cisplatin and new octahedral Pt(IV) complexes.
Kim WK; Kwon YE
Cancer Chemother Pharmacol; 2007 Jul; 60(2):237-43. PubMed ID: 17089165
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)].
Sova P; Chladek J; Zak F; Mistr A; Kroutil A; Semerad M; Slovak Z
Int J Pharm; 2005 Jan; 288(1):123-9. PubMed ID: 15607264
[TBL] [Abstract][Full Text] [Related]
40. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A
Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]